Core Insights - The company, Microelectrophysiology, was founded in 2010 with a focus on cardiac electrophysiology, aiming to introduce advanced arrhythmia treatment solutions to China [2] - The company has achieved significant milestones, including the development of the first domestic and third global magnetic positioning three-dimensional cardiac electrophysiology system, breaking the reliance on imports in this field [3] - In 2022, the company was successfully listed on the Sci-Tech Innovation Board, marking a new chapter in its development [3] - The company has established a comprehensive treatment platform integrating "radiofrequency, cryoablation, and pulsed field" technologies, providing a wide range of quality options for clinical applications [3] - The company has expanded its market presence, with products entering numerous core tertiary hospitals in China and being exported to over 30 countries and regions globally [3] Future Outlook - The company plans to continue its strategy of "technological breakthroughs and global development," focusing on the cardiac electrophysiology field and aiming to launch more leading products and solutions [4] - The company is committed to enhancing its global business layout and contributing to the high-quality development of China's medical device industry [4]